RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis

Who May Qualify: - Elderly males or females aged 65 years or older - diagnosed with osteosarcopenia (sarcopenia diagnosis based on AWGS 2019 guidelines - low appendicular skeletal muscle mass (ASM) by Dual-energy X-ray absorptiometry (DXA) (M:\<7.0kg/m2, F:\<5.4kg/m2) AND low handgrip strength (M:\<28kg, F:\<18kg) OR low physical performance (6-metre walk: \<1.0m/s or 5-time chair stand test ≥ 12 s); osteoporosis diagnosed based on World Health Organization (WHO) criteria with DXA scan T-score ≤ -2.5) - Willing and able to comply with study protocol including follow-up evaluations. Who Should NOT Join This Trial: - history of recent fracture i.e., within 3 months - history of prior anti-osteoporotic drug - disease or medication affecting bone or muscle metabolism - Chairbound or bedbound - Unable to agree for consent - contraindication to drug i.e., Denosumab or Zoledronic Acid - Underlying malignancy or disease known to cause cachexia - severe renal impairment e.g., Creatinine Clearance (CrCl) \< 35ml/min - moderate to severe liver failure (Child-Pugh Class B or C). Always talk to your doctor about whether this trial is right for you.